

AMEND THE ABOVE-IDENTIFIED APPLICATION AS FOLLOWS:



In The Claims:

Cancel claims 1-67.

Amend new claims 68-90 as follows:

-- 68. NEW) A vector comprising a viral vector, a viral vector nucleic acid, or a nucleic acid construct that comprises a viral vector nucleic acid sequence, said vector, which when introduced into a target cell of interest, expresses an exogenous gene or exogenous nucleic acid sequences, wherein said viral vector nucleic acid comprises at least one non-deletion modification with a non-retroviral sequence leading to an alteration or enhancement of viral vector function. -- *non-deletion*

YB
-- 69. (NEW) The vector of claim 68, further comprising one or more native or non-native promoter/enhancer regions which comprise at least one sequence segment. --

-- 70. (NEW) The vector of claim 69, wherein said at least one sequence segment has been modified. --

-- 71. (NEW) The vector of claim 68, further comprising a native or non-native viral vector terminator or processing signal or segment thereof, or both. --

-- 72. (NEW) The vector of claim 71, wherein said native or non-native viral vector terminator or processing signal or segment thereof, or both, have been modified. --

-- 73. (NEW) The vector of claim 68, wherein said non-deletion modification comprises a substitution of a native sequence segment with a non-retroviral sequence segment. --

-- 74. (NEW) The vector of claim 73, wherein the sequence segments in said substitution are not related to promoter/enhancer sequences of a retrovirus.

-- 75. (NEW) The vector of claim 68, wherein said non-deletion modification comprises a mutation selected from the group consisting of a point mutation, an insertion, a substitution and a combination of any of the foregoing.

-- 76. (NEW) The vector of claim 68, wherein said viral vector is a retrovirus. --

-- 77. (NEW) The vector of claims 71 or 72, wherein said terminator, or said processing signal, or both, include a polyadenylation signal. --

-- 78. (NEW) The vector of claim 68, comprising a segment of said viral vector terminator or a segment of said processing signal, or both. -- *No antic sense 12, 2nd*

YB1
-- 79 (NEW) The vector of claim 69, wherein the function of said one or more promoter/enhancers regions have been reduced, inhibited or eliminated. --

-- 80. (NEW). The vector of claim 69, wherein said one or more native or non-native promoter/enhancer regions produce an RNA lacking a polyadenylation signal. --

-- 81. (NEW) The vector of claim 69, wherein said one or more native or non-native promoter/enhancer regions are selected from the group of genes consisting of snRNA, tRNA, rRNA and a combination of any of the foregoing. -- *112, 2nd*

-- 82. (NEW) The vector of claim 81, further comprising one or more gene or gene segment sequences of said snRNA, tRNA or rRNA gene or genes. -- *112, 2nd*

-- 83. (NEW) The vector of claims 81 or 82, wherein said snRNA is selected from the group consisting of U1, U2, U3, U4, U5, U6, U7, U8, U9, U10, U11 and a combination of any of the foregoing. --

-- 84. (NEW) The vector of claim 70, wherein said modification comprises a substitution or replacement of or addition to said one or more native or non-native promoter/enhancer regions with an exogenous gene or an exogenous nucleic acid sequence. --

-- 85. A process for producing the viral vector or viral vector nucleic acid or nucleic acid construct that comprises a viral vector nucleic acid sequence of claim 68, said process comprising the steps of:

providing said vector of claim 1; and

introducing said vector into a packaging cell or a packaging cell line under conditions to produce said viral vector or said viral vector nucleic acid. --

-- 86. (NEW) The process of claim 85, wherein said providing step or introducing step, the nucleic acid construct has been modified in a promoter/enhancer region. --

-- 87. (NEW) The process of claim 85, wherein said providing step or introducing step, the nucleic acid construct has been modified in a non-native promoter/enhancer region. --

-88. (NEW) The process of claim 85, wherein said nucleic acid construct, when introduced into said packaging cell or packaging cell line, stably integrates into the genome of said packaging cell or said packaging cell line. --

-- 89. (NEW) The process of claim 85, wherein said nucleic acid construct has been modified by means of an episome. --

-- 90. (NEW) The process of claim 85, wherein said nucleic acid construct has been modified by means of transient expression. --

* * * * *